Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aromatase inhibitors and bone health in women with breast cancer.

× No keyword cloud information.

40 in total

1. AIs: implications for fractures in perimenopausal women with breast cancer.

Authors: Beatrice J Edwards; Athena Samaras; June M McKoy; Simone Boyle; Charles L Bennett
Journal: Community Oncol Date: 2008-11-01

2. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Authors: R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi
Journal: Osteoporos Int Date: 2012-01-20 Impact factor: 4.507

Review 3. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.

Authors: Tariq Chukir; Yi Liu; Azeez Farooki
Journal: Br J Clin Pharmacol Date: 2019-01-25 Impact factor: 4.335

4. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Authors: Landry K Kamdem; Jingyue Xi; Brandi L Clark; Bryana J Gregory; Kelley M Kidwell; Ana-Maria Storniolo; Vered Stearns; Daniel F Hayes; Christina L Gersch; James M Rae; N Lynn Henry; Daniel L Hertz
Journal: Breast Cancer Res Treat Date: 2019-02-12 Impact factor: 4.872

5. Heel ultrasound can assess maintenance of bone mass in women with breast cancer.

Authors: Gabrielle A Langmann; Karen T Vujevich; Donna Medich; Megan E Miller; Subashan Perera; Susan L Greenspan
Journal: J Clin Densitom Date: 2012-03-16 Impact factor: 2.617

6. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.

Authors: B J Gregory; S M Chen; M A Murphy; D H Atchley; L K Kamdem
Journal: J Clin Pharm Ther Date: 2017-07-29 Impact factor: 2.512

7. Overuse of short-interval bone densitometry: assessing rates of low-value care.

Authors: N E Morden; W L Schpero; R Zaha; T D Sequist; C H Colla
Journal: Osteoporos Int Date: 2014-05-09 Impact factor: 4.507

Review 8. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know.

Authors: Susan Hong; Aarati Didwania; Olufunmilayo Olopade; Pamela Ganschow
Journal: J Gen Intern Med Date: 2009-11 Impact factor: 5.128

9. Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.

Authors: Selma Masri; Ki Lui; Sheryl Phung; Jingjing Ye; Dujin Zhou; Xin Wang; Shiuan Chen
Journal: Breast Cancer Res Treat Date: 2008-08-03 Impact factor: 4.872

10. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.

Authors: N L Henry; A Nguyen; F Azzouz; L Li; J Robarge; S Philips; D Cao; T C Skaar; J M Rae; A M Storniolo; D A Flockhart; D F Hayes; V Stearns
Journal: Br J Cancer Date: 2009-12-01 Impact factor: 7.640